

CORRECTION

Open Access

# Correction: phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis -KOGC04-

Satoru Matsuda<sup>1</sup>, Tsunehiro Takahashi<sup>1\*</sup>, Junichi Fukada<sup>2</sup>, Kazumasa Fukuda<sup>1</sup>, Hirofumi Kawakubo<sup>1</sup>, Yoshiro Saikawa<sup>1</sup>, Osamu Kawaguchi<sup>2</sup>, Hiroya Takeuchi<sup>1</sup>, Naoyuki Shigematsu<sup>2</sup> and Yuko Kitagawa<sup>1</sup>

## Correction

After the publication of this work [1], we noted that owing to an inadvertent mistake, the description of the chemotherapy schedule shown in the Methods was different from that shown in the Abstract and the duration of S-1 treatment in the initial chemoradiotherapy was inadequately described in Figure 1. Therefore, Methods and Figure 1 were modified accordingly.


In the “Chemoradiotherapy” section in the Methods, the 1st and 3rd paragraphs should read as follows:

“The chemoradiotherapy protocol consisted of administration of S-1 plus biweekly cisplatin and radiation (Figure 1). The initial chemoradiotherapy schedule was for 6 weeks: S-1 was orally administered twice daily from the evening of day 1 to the morning of day 15, and the total dose was based on the patient’s body surface area

(BSA), as follows: <1.25 m<sup>2</sup>, 80 mg; 1.25–1.5 m<sup>2</sup>, 100 mg; and >1.5 m<sup>2</sup>, 120 mg. An escalating dose of cisplatin was administered by infusion over 1 h on days 1 and 15 without infusional hydration. The starting dose (level 1) of cisplatin was 15 mg/m<sup>2</sup>, the second dose (level 2) was 20 mg/m<sup>2</sup>, and the third dose (level 3) was 25 mg/m<sup>2</sup>.“

“After initial chemoradiotherapy, one cycle of combination chemotherapy with S-1 plus biweekly cisplatin was delivered. This consisted of 42 days of S-1 administered from the evening of day 1 to the morning of day 29 and of cisplatin administered on days 1, 15, and 29.”

In “Figure 1,” based on the description in the manuscript, the duration of S-1 treatment in the initial chemoradiotherapy was revised to 1–15 days from 1–22 days (Figure 1).



**Figure 1** Chemoradiotherapy consisted of combination chemotherapy with S-1, biweekly cisplatin, and fractionated radiation therapy.

\* Correspondence: [surgeontsune@yahoo.co.jp](mailto:surgeontsune@yahoo.co.jp)

<sup>1</sup>Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

Full list of author information is available at the end of the article

**Author details**

<sup>1</sup>Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. <sup>2</sup>Department of Radiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Received: 16 June 2014 Accepted: 16 June 2014

Published: 25 June 2014

**Reference**

1. Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y: Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-. *Radiat Oncol* 2014, **9**:9.

doi:10.1186/1748-717X-9-140

**Cite this article as:** Matsuda et al.: Correction: phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis -KOGC04-. *Radiation Oncology* 2014 9:140.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

